All In Biotech

Free tool

FAERS Monitor: Cardura Xl

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021269 or its brand name (Cardura Xl, Doxazosin Mesylate). Reports on generic versions are filed under their own applications.

Reports

15,500

Serious

12,187

79% of reports

Hospitalization

6,573

Death reported

1,476

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea882
  • fatigue762
  • dizziness744
  • diarrhoea726
  • drug ineffective714
  • asthenia695
  • nausea628
  • hypotension623
  • headache523
  • hypertension522
  • fall487
  • pain469
  • death463
  • drug interaction461
  • vomiting449

Reports by year received

View as table
YearReports
2004595
2005514
2006575
2007738
2008652
2009708
2010878
20111,142
2012999
2013471
2014598
2015738
2016694
2017572
2018758
2019694
2020619
2021610
2022775
2023584
2024655
2025540
2026391

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,659 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypotensionSignal6234.23.91,540
drug interactionSignal4614.03.61,018
hypertensionSignal5223.43.1865
astheniaSignal6952.52.3641
dyspnoeaSignal8822.12.0531
dizzinessSignal7442.01.9394
fall4872.01.8241
diarrhoea7261.51.4135
fatigue7621.31.264
vomiting4491.31.231
headache5231.11.08
nausea6281.11.03
pain4691.00.91
drug ineffective7140.70.772
death4630.70.748

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.